Navco Pharmaceuticals Inc.
NAV.V
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 31.70K | 33.90K | 37.00K | 599.60K | 686.30K |
| Depreciation & Amortization | 0.00 | 500.00 | 1.00K | -27.80K | -2.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.70K | 34.40K | 38.00K | 571.80K | 684.00K |
| Operating Income | -31.70K | -34.40K | -38.00K | -571.80K | -684.00K |
| Income Before Tax | -53.00K | -53.70K | -57.00K | -670.90K | -792.50K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.05 | -0.05 | -0.06 | -0.67 | -0.79 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -53.00K | -53.70K | -57.00K | -670.90K | -792.50K |
| EBIT | -31.70K | -34.40K | -38.00K | -571.80K | -684.00K |
| EBITDA | -10.90K | -15.20K | -19.80K | -553.40K | -651.30K |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 228.28M | 228.28M | 228.28M | 228.31M | 226.66M |
| Average Diluted Shares Outstanding | 228.28M | 228.28M | 228.28M | 228.31M | 226.66M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |